Gregory Harriman
Partner and Chief Investment Officer @ BioAdvance
Wayne, United States
Gregory Harriman is a seed investor at BioAdvance in Wayne focused on Biotechnology and Medical. Greg is the president of Main Line Ventures, an investment and consultancy company offering funding, technical expertise, and executive management experience to entrepreneurs and early stage bioscience and healthcare companies in the Mid-Atlantic region. Greg is an accomplished executive with over 20 years of experience with increasingresponsibilities in academic medicine and biopharmaceutical companies. He received his medical degree from the University of California, San Diego and trained at Washington University in St. Louis, MO and the National Institutes of Health in Bethesda, MD. He is board-certified in internal medicine, infectious diseases, and clinical & laboratory immunology. He previously had a successful academic career at the NIH and Baylor College of Medicine, having published over 40 articles and book chapters, receiving NIH and private foundation grant funding, and performing innovative, significant research in immunology, vaccines, and immune-mediated diseases. He is a fellow of the American College of Physicians and is a member of several other professional medical organizations, including the American Academy of Asthma, Allergy & Immunology. He has held leadership positions in several small and large biopharmaceutical companies having global experience in the successful research and development of pharmaceuticals, biologics, medical devices and cell therapies, including a multi-billion dollar product for treatment of immune-related diseases.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Gregory Harriman invests in
Stages Gregory Harriman invests in
Countries Gregory Harriman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (67%)
- Medical 1 (33%)
- Health Care 1 (33%)
- Health Diagnostics 1 (33%)
- Information Technology 1 (33%)
Stage
- Seed 1 (33%)
- Venture - Series Unknown 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device. | $1.9M / Seed / Dec 12, 2022 | ||
| Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device. | $2M / Seed / Jul 21, 2022 | ||
| A biotech company, engages in developing monoclonal antibodies to treat fibrotic and remodeling diseases. The company was founded in 2012 and is headquartered in Bryn Mawr, Pennsylvania . | $500K / Venture - Series Unknown / Sep 25, 2017 |
Co-Investors
About BioAdvance
BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund. They invest in therapeutics, devices, diagnostics and platform technologies focused on human health.Since its first investments in 2003, BioAdvance has become one of the nation's leading investorsproviding pre-seed and seed-stage funding. To date they have committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies.
BioAdvance Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Shahram Hejazi
Partner
|
|||
|
Gregory Harriman
Partner and Chief Investment Officer
|
|||
Jeff Edelson
Entrepreneur in Residence / Scientific Liason
|
|||
Marnie McCoy
Program Director
|
|||
Robert P. Driscoll
Director of Finance
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Gregory Harriman invest in?
Gregory Harriman invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gregory Harriman?
Public channels for Gregory Harriman include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gregory Harriman last invest?
The most recent investment recorded for Gregory Harriman closed in Dec 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
